Related Experiment Video

Updated: Apr 17, 2026

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

20.3K

The Potential of panHER Inhibition in Cancer

Xiaochun Wang1, Kathleen M Batty1, Philip J Crowe1

  • 1Sarcoma Nano-Oncology Group, Adult Cancer Program, Lowy Cancer Research Centre, Prince of Wales Clinical School, University of New South Wales (UNSW) , Sydney, NSW , Australia ; Department of Surgery, Prince of Wales Clinical School, University of New South Wales (UNSW) , Sydney, NSW , Australia.

Frontiers in Oncology
|February 13, 2015
PubMed
Abstract

Insights

Targeting all HER family receptors (panHER) offers a promising cancer therapy approach. PanHER inhibitors show potential to overcome resistance and improve outcomes in solid tumors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Signaling

Background:

  • Hyper-activation of human epidermal growth factor (HER) receptors (HER1-4) drives key cancer signaling pathways.
  • Targeting individual HER receptors like HER1/EGFR shows limited efficacy due to resistance mechanisms such as secondary mutations or bypass signaling.
  • The development of panHER inhibitors aims to overcome these limitations by blocking multiple HER family members simultaneously.

Purpose of the Study:

  • To review the role of HER signaling pathways in tumor progression.
  • To examine the progress and potential of panHER inhibition as a cancer treatment strategy.

Main Methods:

  • A comprehensive literature review was conducted using PubMed and Medline databases.
  • Studies on HER signaling pathways and panHER inhibition were critically analyzed.

Main Results:

  • Pre-clinical studies and clinical trials indicate that panHER inhibitors yield promising results.
  • These inhibitors demonstrate potential for improving patient outcomes in various solid cancers.

Conclusions:

  • PanHER inhibition represents a novel therapeutic direction for cancers with HER-family hyper-activation.
  • This approach holds significant potential for future clinical cancer therapy, particularly in epithelial cancers and sarcomas.
Keywords:
EGFRHER signaling pathwaysdrug resistancepanHER inhibitorstargeted therapy

More Related Videos

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

1.6K
In Vitro Modeling of Cancerous Neural Invasion: The Dorsal Root Ganglion Model08:23

In Vitro Modeling of Cancerous Neural Invasion: The Dorsal Root Ganglion Model

Published on: April 12, 2016

10.2K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.3K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

5.7K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
8.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K